Pioglitazone inhibits platelet function and potentiates the effects of aspirin: A prospective observation study

Thrombosis Research

Volumn 129, Issue 6, 2012, Pages 760-764

  Mongan, John ^a   Mieszczanska, Hanna Z ^a   Smith, Brian H ^a   Messing, Susan P ^a   Phipps, Richard P ^a   Francis, Charles W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

aspirin; pioglitazone; platelet function; platelet release; thiazolidinediones

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; ARACHIDONIC ACID; CD40 LIGAND; COLLAGEN; PIOGLITAZONE; THROMBOXANE B2; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; THROMBOCYTE FUNCTION;

ASPIRIN; BLOOD PLATELETS; CASE-CONTROL STUDIES; DIABETES MELLITUS; DRUG SYNERGISM; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; PROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 84861335599     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.12.019     Document Type: Article

References (33)

1. H. Yki-Jarvinen Thiazolidinediones N Engl J Med 351 11 2004 1106 1118
2. F. Akbiyik Human bone marrow megakaryocytes and platelets express PPARgamma, and PPARgamma agonists blunt platelet release of CD40 ligand and thromboxanes Blood 104 5 2004 1361 1368
3. S.Z. Duan, M.G. Usher, and R.M. Mortensen Peroxisome proliferator- activated receptor-gamma-mediated effects in the vasculature Circ Res 102 3 2008 283 294
4. A. Pfützner, N. Marx, G. Lübben, M. Langenfeld, D. Walcher, T. Konrad, and T. Forst Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study J Am Coll Cardiol 45 12 2005 1925 1931
5. H. Mieszczanska, N.K. Kaba, C.W. Francis, J.E. Gerich, R. Dodis, K.Q. Schwarz, R.P. Phipps, B.H. Smith, M. Lee, S. Messing, and M.B. Taubman Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non-diabetic patients with coronary artery disease J Thromb Haemost 5 5 2007 942 949
6. M.R. Langenfeld, T. Forst, C. Hohberg, P. Kann, G. Lübben, T. Konrad, S.D. Füllert, C. Sachara, and A. Pfützner Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study Circulation 111 19 2005 2525 2531
7. R.A. DeFronzo, D. Tripathy, D.C. Schwenke, M. Banerji, G.A. Bray, T.A. Buchanan, S.C. Clement, R.R. Henry, H.N. Hodis, A.E. Kitabchi, W.J. Mack, S. Mudaliar, R.E. Ratner, K. Williams, F.B. Stentz, N. Musi, P.D. Reaven ACT NOW Study Pioglitazone for diabetes prevention in impaired glucose tolerance N Engl J Med 364 12 2011 1104 1115
8. J.A. Dormandy, B. Charbonnel, D.J. Eckland, E. ERdmann, M. Massi-Benedetti, I.K. Moules, A.M. Skene, M.H. TAn, P.J. Lefèbvre, G.D. Murray, E. Standl, R.G. Wilcox, L. Wilheimsen, J. Betteridge, K. Birkeland, A. Golay, R.J. Heine, L. Korányi, M. Lasakso, M. Mokán, A. Norkus, V. Pirags, T. Podar, A. Scheen, W. Scherbaum, G. Schernthaner, O. Schmitz, J. Skrha, U. Smith, J. Taton PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 9493 2005 1279 1289
9. D. Choi, S.K. Kim, S.H. Choi, Y.G. Ko, C.W. Ahn, Y. Jang, S.K. Lim, H.C. Lee, and B.S. Cha Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes Diabetes Care 27 11 2004 2654 2660
10. E. Erdmann, J.A. Dormandy, B. Charbonnel, M. Massi-Benedetti, I.K. Moules, A.M. Skene PROactive Investigators The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study J Am Coll Cardiol 49 17 2007 1772 1780
11. R. Rios-Vázquez, R. Marzoa-Revas, I. Gil-Ortega, and J.C. Kaski Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus Am J Cardiovasc Drugs 6 4 2006 231 242
12. Z.M. Ruggeri Platelets in atherothrombosis Nat Med 8 11 2002 1227 1234
13. P.F. Bodary, F.B. Vargas, S.A. King, K.L. Jongeward, K.J. Wickenheiser, and D.T. Eitzman Pioglitazone protects against thrombosis in a mouse model of obesity and insulin resistance J Thromb Haemost 3 10 2005 2149 2153
14. D. Li, K. Chen, N. Sinha, X. Zhang, Y. Wang, A.K. Sinha, F. Romeo, and J.L. Mehta The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation Cardiovasc Res 65 4 2005 907 912
15. T. Ishizuka, S. Itaya, H. Wada, M. Ishizawa, M. Kimura, K. Kajita, Y. Kanoh, A. Miura, N. Muto, and K. Yasuda Differential effect of the antidiabetic thiazolidinediones troglitazone and pioglitazone on human platelet aggregation mechanism Diabetes 47 9 1998 1494 1500
16. M.P. Khanolkar, R.H. Morris, A.W. Thomas, H. Bolusani, A.W. Roberts, J. Geen, S.K. Jackson, and L.M. Evans Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus-an effect probably mediated by direct platelet PPARgamma activation Atherosclerosis 197 2 2008 718 724
17. J.S. Sidhu, D. Cowan, and J.C. Kaski Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus Am J Cardiol 94 2 2004 151 156
18. F.Y. Ali, P.C. Armstrong, A.R. Dhanji, A.T. Tucker, M.J. Paul-Clark, J.A. Mitchell, and T.D. Warner Antiplatelet actions of statins and fibrates are mediated by PPARs Arterioscler Thromb Vasc Biol 29 5 2009 706 711
19. W. Chokesuwattanaskul, Y. Yaqub, J.A. Suarez, J. Simoni, G. Simoni, K.M. Nugent, R. Jimenez, and A. Perez-Verdia Effect of pioglitazone on platelet aggregation in a healthy cohort Cardiology 116 4 2010 253 256
20. M. Pignone, M.J. Alberts, J.A. Colwell, M. Cushman, S.E. Inzucchi, D. Mukherjee, R.S. Rosenson, C.D. Williams, P.W. Wilson, M.S. Kirkman American Diabetes Association American Heart Association American College of Cardiology Foundation Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation Diabetes Care 33 6 2010 1395 1402
21. G.V. Born Aggregation of blood platelets by adenosine diphosphate and its reversal Nature 194 1962 927 929
22. P.A. Gum, K. Kottke-Marchant, P.A. Welsh, J. White, and E.J. Topol A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease J Am Coll Cardiol 41 6 2003 961 965
23. Y. Miyazaki, A. Mahankali, M. Matsuda, L. Glass, S. Mahankali, E. Ferrannini, K. Cusi, L.J. Mandarino, and R.A. DeFronzo Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone Diabetes Care 24 4 2001 710 719
24. G. Shi, and C.N. Morrell Platelets as initiators and mediators of inflammation at the vessel wall Thromb Res 127 5 2011 387 390
25. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 24 2007 2457 2471
26. D.J. Graham, R. Ouellet-Hellstrom, T.E. MaCurdy, F. Ali, C. Sholley, C. Worrall, and J.A. Kelman Risk of Acute Myocardial Infarction, Stroke, Heart Failure, and Death in Elderly Medicare Patients Treated with Rosiglitazone or Pioglitazone JAMA 304 4 Jul 28, 2010 411 418
27. G.J. Hankey, and J.W. Eikelboom Aspirin resistance Lancet 367 9510 2006 606 617
28. S.B. Mortensen, S.B. Larsen, E.L. Grove, S.D. Kristensen, and A.M. Hvas Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus Thromb Res 126 4 2010 e318 e322
29. D.J. Angiolillo, A. Fernandez-Ortiz, E. Bernardo, C. Ramirez, M. Sabaté, P. Jimenez-Quevedo, R. Hernández, R. Moreno, J. Escaned, F. Alfonso, C. Bañuelos, M.A. Costa, T.A. Bass, and C. Macaya Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment Diabetes 54 8 2005 2430 2435
30. A. Markiewicz, and K. Semenowicz Time dependent changes in the pharmacokinetics of aspirin Int J Clin Pharmacol Biopharm 17 10 1979 409 411
31. A.K. Pedersen, and D.A. FitzGerald Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase N Engl J Med 311 19 1984 1206 1211
32. G.J. Roth, N. Stanford, and P.W. Majerus Acetylation of prostaglandin synthase by aspirin Proc Natl Acad Sci U S A 72 8 1975 3073 3076
33. P. Mojaverian Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time Clin Pharmacol Ther 41 1 Jan 1987 11 17